A Phase 2 proof-of-concept trial evaluating the efficacy of XEN901 as a treatment for adult focal seizures

Trial Profile

A Phase 2 proof-of-concept trial evaluating the efficacy of XEN901 as a treatment for adult focal seizures

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs XEN 901 (Primary)
  • Indications Seizures
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to a Xenon Pharmaceuticals media release, this trial is expected to begin by year-end 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top